# RFA Plus Carrizumab vs Carrizumab Alone for HCC

> **NCT04150744** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 120 (estimated)

## Conditions studied

- Tumor Immunity
- Immunosuppression
- Radiofrequency Ablation

## Interventions

- **COMBINATION_PRODUCT:** radiofrequency ablation

## Key facts

- **NCT ID:** NCT04150744
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150744, "RFA Plus Carrizumab vs Carrizumab Alone for HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04150744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*